What You Should Know:– Pfizer Inc. and Metsera, Inc. have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company focused on developing medicines for obesity and cardiometabolic diseases for $4.9B. – The acquisition is a strategic move for Pfizer, allowing it to enter a significant and growing therapeutic area. There are also two oral GLP-1 RA candidates that are expected to begin clinical trials imminently. “Since our founding in 2022, Metsera has worked tirelessly to reduce the physical, emotional, and economic burdens of obesity with a portfolio of next generation nutrient-stimulated hormone therapeutic candidates. We look forward to joining forces with Pfizer to leverage their global clinical, regulatory, manufacturing and commercial capabilities to realize the promise of improved human health at scale.”